Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Cancer Lett. 2009 May 15;284(2):175–181. doi: 10.1016/j.canlet.2009.04.022

Figure 5.

Figure 5

4HPR inhibits differentiation of primary human osteoclast precursors. A, B) Human osteoclast precursors were cultured in osteoclastic growth media (see “Materials and Methods”) in the presence or absence of indicated concentrations of 4HPR for 7 days. Osteoclast differentiation was determined by counting the number of multinucleated TRAP-expressing osteoclasts. As shown in A, numerous osteoclasts were formed in cultures treated with vehicle (Control) but not 4HPR (original magnification ×100). 4HPR reduced number of osteoclasts in a dose-dependent manner.